The Food and Drug Administration (FDA) approved Narcan, 4 milligram (mg) nasal spray for over-the-counter sale. Narcan is a nasal spray version of naloxone, a rescue medicine that can be administered in the event of an opioid ...
Mar 30, 2023
0
2
The U.S. Food and Drug Administration on Wednesday approved the over-the-counter use of a nasal spray that can reverse an opioid overdose.
Mar 29, 2023
0
2
Detailed PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may irradiate ...
Mar 24, 2023
0
5
To combat the fentanyl epidemic in the United States, researchers at the University of Houston have created a fentanyl vaccine that could help prevent overdoses. They aim to test the vaccine in a human trial within the next ...
Feb 9, 2023
0
2
Clinical trials have started for the first prosthetic pulmonary valve replacement that is specifically designed for pediatric patients and can expand over time inside a child's anatomy.
Feb 6, 2023
0
13
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted ...
Jan 31, 2023
0
73
Cribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways. Research from Vanderbilt-Ingram Cancer Center has revealed new information ...
Oct 27, 2022
0
66
Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.
Oct 20, 2022
0
3
Expected to be diagnosed in 2% of men and 1% of women in the U.S., kidney cancer has traditionally been one of the most challenging cancers to treat. Until 2005, only one drug had been approved by the Food and Drug Administration ...
Oct 14, 2022
0
4
Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer's drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than ...
Oct 14, 2022
0
5
